CCA EDUCATE

CHOLANGIOCARCINOMA AUSTRALASIA

COMPILED BY
Steve Holmes
Email: Steve

Ph: +61415153522
FB Messenger
FB Page Steveholmes

RESEARCH | MUTATIONS | TREATMENT | SURGERY

Please help us to

  • EQUIP: Every "Newly Diagnosed Patient" with a Cancer Tool Kit immediately upon diagnosis.
  • EMPOWER: All who are connected or impacted  by one Cancer Diagnosis.
  • CONNECT: Newly Diagnosed Patients and Caregivers to our Globally Community

Ensuring that the Newly Diagnosed Patient are empowered with todays lifesaving information, TODAY!

Help by sharing this link

We need your help and feedback

Please help us improve our content and delivery

Rate this page...


Easy to followHard To followHelpedDid not help

Are you a . . .


PatientCaregiverFamily/FriendDoctorNurseOther

How can we improve this?


TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival

  • WHAT: IDHI Mutations
  • WHY: Breakthrough
  • HOW: Trial Success

1DH1 and TIBSOVO® (ivosidenib)

Primary End Point Achieved

Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients – TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo – “Advanced cholangiocarcinoma is a life-threatening disease with no currently approved treatment options,” said Chris Bowden, M.D., chief medical officer at Agios. “The data from the ClarIDHy Phase 3 trial demonstrate the clinically significant benefit of TIBSOVO® in patients with this challenging disease who harbor the IDH1 mutation.

View Media Release

Phase 3 trial sees significant benefit

“The data from the ClarIDHy Phase 3 trial demonstrate the clinically significant benefit of TIBSOVO® in patients with this challenging disease who harbor the IDH1 mutation. We are committed to working with regulators to bring this potential treatment option to patients as quickly as possible. We thank the patients and physicians who participated in the ClarIDHy study, without whom this important advancement would not be possible.”

View Media Release

Cancer Tool Kits

Newly Diagnosed?

7 Must Do Steps
Cancer Tool Kits @ www.thepcancertoolkit.com
Cancer Tool Kits